Aimmune Therapeutics (NASDAQ:AIMT) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.89) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.03, Briefing.com reports.
Shares of NASDAQ:AIMT opened at $30.29 on Friday. Aimmune Therapeutics has a 12 month low of $24.56 and a 12 month high of $42.00. The stock has a market capitalization of $1.88 billion, a P/E ratio of -11.61 and a beta of -0.10.
A number of brokerages recently commented on AIMT. Credit Suisse Group set a $40.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Friday. BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. Wedbush began coverage on shares of Aimmune Therapeutics in a report on Wednesday, October 17th. They issued a “buy” rating and a $72.00 price target for the company. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $50.70.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Recommended Story: Growth Stocks
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.